DIRS.INFO The most relevant business & tech news

TD Cowen raised its price target on Netflix, calling for 13% upside for the stock. JPMorgan analyst Rachel Vatnsdal was similarly bullish with her $42 price target, while Morgan Stanley analyst Tejas Savant set a price target of $44. The analyst also raised his price target to $42 from $37, indicating a potential 3% upside from the stock's Monday afternoon close. — Lisa Kailai Han 5:44 a.m.: TD Cowen lifts Netflix price target ahead of second-quarter earnings announcement TD Cowen expects more gains ahead for Netflix . NFLX YTD mountain NFLX year to date — Lisa Kailai Han 5:44 a.m.: KeyBanc hikes Nvidia price target The good times for Nvidia are not over yet, according to KeyBanc.

Persons: TD Cowen, KeyBanc, Morgan Stanley, Bank of America Michael Ryskin, Ryskin, Rachel Vatnsdal, Tejas Savant, Morgan Stanley's Savant, William Blair, Stifel, Lisa Kailai Han, Wells, Donald Fandetti, Fandetti, — Lisa Kailai Han, Grayson, Daniel Lungo, Piper Sandler, Scott Siefers, BAC's NII, Siefers, JPMorgan Chase, Cowen, John Blackledge, Blackledge, John Vinh, Fred Imbert Organizations: CNBC, Netflix, Nvidia, Wall, Tempus, Nasdaq, JPMorgan, Bank of America, Precision Oncology, Needham, American Express, Devon Energy, of America, Citigroup, Blackwell, Wolfe Research, UBS Locations: Devon, Williston, Netflix's, Monday's, 2H24, GB200

☆ Wall Street analysts love this recent IPO that's an AI play in the health-care sector
▼ + stars: | 2024-07-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Wall Street analysts are bullish on recently launched health-care technology stock Tempus AI . By combining a patient's molecular, clinical, and imaging data with its AI platform, Tempus delivers personalized therapy decisions," he wrote. Tempus AI debuted at the Nasdaq on June 14, closing at $40 after pricing its initial public offering at $37. Last month, investment management firm SoftBank announced it had invested about $200 million in Tempus AI before its Nasdaq listing. Since its debut, Tempus AI stock has slipped 10% from its IPO price.

Persons: Michael Ryskin, SoftBank, America's Ryskin, Ryskin, JPMorgan's Rachel Vatnsdal, William Blair, Morgan Stanley, Tejas Savant, TD Cowen, Dan Brennan Organizations: Bank of America, Tempus, Nasdaq, America's, Precision Oncology, Loop Capital Locations: Stifel, Needham

☆ Weight-loss drugs fuel boom for firms that fill syringes
▼ + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.

Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York

Search resuls for: "Tejas Savant"

3 mentions found